EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses

Jean-Pierre Pouget, Pablo Minguez Gabina, Ken Herrmann, Desirée Deandreis, Mark Konijnenberg, David Taieb, Fijs W B van Leeuwen, Jens Kurth, Uta Eberlein, Michael Lassmann, Katharina Lückerath, EANM Radiobiology Working Group

European Journal of Nuclear Medicine and Molecular Imaging · 2025-02 · 52 (3) · 1210-1222

DOI: 10.1007/s00259-024-06963-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 12.11.2024. Verfasst von Jean-Pierre Pouget und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM…. Hauptthemen laut MEDLINE: Radiobiology, Clinical Trials as Topic, Nuclear Medicine, Research Design. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SIRIC Montpellier Cancer: Grant, Prostate Cancer Foundation, Ligue Contre le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study by the EANM radiobiology working group aims to analyze the efficacy and toxicity of targeted radionuclide therapy (TRT) using radiopharmaceuticals approved by the EMA and FDA for neuroendocrine tumors and prostate cancer. It seeks to understand the correlation between physical parameters such as absorbed dose and TRT outcomes, alongside other biological factors.

Methods

We reviewed clinical studies on TRT, focusing on the relationship between physical parameters and treatment outcomes, and applying basic radiobiological principles to radiopharmaceutical therapy to identify key factors affecting therapeutic success.

Results

The analysis revealed that mean absorbed dose alone is insufficient to predict treatment response or toxicity. For absorbed doses below a certain threshold, outcomes are unpredictable, while doses above this threshold improve the likelihood of biological responses. However, even at higher absorbed doses, response plateaus indicate the need for additional parameters to explain outcome variability, including heterogeneity in target expression, anatomical disease location, (epi)genetics, DNA repair capacity, and the tumor microenvironment, aspects that will be discussed in Part II of this analysis.

Conclusion

Understanding radiobiology is crucial for optimizing TRT. More dosimetric data is needed to refine treatment protocols. While absorbed dose is critical, it alone does not determine TRT outcomes. Future research should integrate biological parameters with physical dosimetry to enhance efficacy and minimize toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiobiologyClinical Trials as TopicNuclear MedicineResearch DesignHumansDose-Response Relationship, RadiationRadiopharmaceuticalsProstatic NeoplasmsRadiotherapy Dosage

Stichwörter der Autor:innen

BiomarkersDosimetryRadiobiologyRadiopharmaceutical therapyRadiopharmaceuticals

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université de Montpellier, Institut Régional du Cancer de Montpellier (ICM), Montpellier, France. Equipe Labellisée Ligue Contre Le Cancer, INSE…
  • Department of Medical Physics and Radiation Protection, Gurutzeta-Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, Spain.
  • Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
  • Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Paris Saclay University, 114 Rue Edouard Vaillant, Villejuif, France.
  • Radiology & Nuclear Medicine Department, Erasmus MC, Rotterdam, The Netherlands.
  • Nuclear Medicine Diagnostic Imaging and Endoradiotherapy Center Aix-Marseille University CHU de La Timone, Marseille Cedex 5, Marseille, France.

Förderung

  • SIRIC Montpellier Cancer: Grant
  • Prostate Cancer Foundation
  • Ligue Contre le Cancer
  • Universitätsklinikum Essen

Zitieren

APA

Pouget, J. P., Gabina, P. M., Herrmann, K., Deandreis, D., Konijnenberg, M., Taieb, D., van Leeuwen, F. W. B., Kurth, J., Eberlein, U., Lassmann, M., Lückerath, K., & EANM Radiobiology Working Group (2025). EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses. European Journal of Nuclear Medicine and Molecular Imaging, 52(3), 1210-1222. https://doi.org/10.1007/s00259-024-06963-9

Vancouver

Pouget JP, Gabina PM, Herrmann K, Deandreis D, Konijnenberg M, Taieb D, et al. EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(3):1210-1222. doi:10.1007/s00259-024-06963-9

BibTeX
@article{Pouget2025,
  author = {Pouget, Jean-Pierre and Gabina, Pablo Minguez and Herrmann, Ken and Deandreis, Desirée and Konijnenberg, Mark and Taieb, David and van Leeuwen, Fijs W B and Kurth, Jens and Eberlein, Uta and Lassmann, Michael and Lückerath, Katharina and EANM Radiobiology Working Group, EANM Radiobiology Working Group},
  title = {EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose–response and threshold absorbed doses},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {3},
  pages = {1210--1222},
  doi = {10.1007/s00259-024-06963-9}
}
Kostenlos starten →